Literature DB >> 7091317

Dopamine decreases fluid reabsorption in straight portions of rabbit proximal tubule.

E Bello-Reuss, Y Higashi, Y Kaneda.   

Abstract

The effects of DA and DA blockers on fluid transport, transepithelial potential difference (PD), and Na fluxes were studied in straight portions of the rabbit proximal tubule by the technique of microperfusion in vitro. DA (10(-6) M) added to the bath (rabbit serum) produced a significant decrease in fluid reabsorption (Jv, nl.min-2.mm-1) from 0.53 +/- 0.05 to 0.19 +/- 0.06 (n = 7, P less than 0.005). PD decreased from -2.7 +/- 0.5 to -1.2 +/- 0.4 mV (P less than 0.01). Drugs active on DA receptors were used to characterize the action of dopamine. Haloperidol (10(-8) M), lisuride (1.5 X 10(-9) M), and metoclopramide (10(-7) M) did not modify Jv by themselves but prevented the action of dopamine. Agonists of DA, Epinine and A 6,7 DTN, produced smaller or shorter decreases in Jv. A 6,7 DTN was active in the presence of alpha- and beta-adrenergic blockers. The serotonin antagonist methysergide decreases Jv by itself by 15%; in its presence DA was not effective. The effect of DA was accompanied by reductions of net Na flux and unidirectional lumen-to-bath and bath-to-lumen Na fluxes by approximately 25%. It is concluded that DA exerts a direct inhibitory effect on fluid transport by the pars recta. The evidence for the existence of DA receptor sites is not conclusive. The mechanism of action is uncertain, but an impairment of transcellular salt transport can be suggested.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7091317     DOI: 10.1152/ajprenal.1982.242.6.F634

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  31 in total

1.  Effects of 20-HETE and 19(S)-HETE on rabbit proximal straight tubule volume transport.

Authors:  R Quigley; M Baum; K M Reddy; J C Griener; J R Falck
Journal:  Am J Physiol Renal Physiol       Date:  2000-06

2.  Effect of protein ingestion on urinary dopamine excretion. Evidence for the functional importance of renal decarboxylation of circulating 3,4-dihydroxyphenylalanine in man.

Authors:  M Williams; J B Young; R M Rosa; S Gunn; F H Epstein; L Landsberg
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

Review 3.  Molecular mechanisms and regulation of urinary acidification.

Authors:  Ira Kurtz
Journal:  Compr Physiol       Date:  2014-10       Impact factor: 9.090

4.  Defective dopamine-1 receptor adenylate cyclase coupling in the proximal convoluted tubule from the spontaneously hypertensive rat.

Authors:  S Kinoshita; A Sidhu; R A Felder
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

5.  The effects of intravenous L-dopa on plasma renin activity, renal function, and blood pressure in man.

Authors:  D Worth; J Harvey; J Brown; M Lee
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension.

Authors:  J N Harvey; D P Worth; J Brown; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

7.  Mechanisms of dopamine effects on Na-K-ATPase activity in Madin-Darby canine kidney (MDCK) epithelial cells.

Authors:  M Shahedi; K Laborde; S Azimi; S Hamdani; C Sachs
Journal:  Pflugers Arch       Date:  1995-04       Impact factor: 3.657

8.  Chronic regulation of the renal Na(+)/H(+) exchanger NHE3 by dopamine: translational and posttranslational mechanisms.

Authors:  Ming Chang Hu; Francesca Di Sole; Jianning Zhang; Paul McLeroy; Orson W Moe
Journal:  Am J Physiol Renal Physiol       Date:  2013-02-20

9.  Dopamine inhibits Na/K-ATPase in single tubules and cultured cells from distal nephron.

Authors:  F Takemoto; H T Cohen; T Satoh; A I Katz
Journal:  Pflugers Arch       Date:  1992-07       Impact factor: 3.657

10.  A quantitative method of evaluating the diuretic response to furosemide in rats.

Authors:  R Hori; K Okumura; K Inui; T Shibata; T Kikkoji; A Kamiya
Journal:  Pharm Res       Date:  1988-11       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.